Top 50 Biotech VC Funds in Germany
A list of 50 VC funds that invest in Biotech startups based in Germany. We rank investors based on the number of investments they made in Biotech companies from Germany. We update this investor list every month.Top 50 Biotech VC Funds in Germany
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.
Show more
Investment focus
- Software, Information Technology, Biotechnology
- Seed, Series A, Funding Round
- Germany, Switzerland, United States
Portfolio highlights
- RAYDIAX — We are Raydiax.Interventional only.Our goal is to reinvent computer tomography that is focussed on treatment.
- Inovedis — Inovedis offers innovative solutions in medical technology that contribute both to optimized patient care as well as time and cost reductions in the healthcare sector.
- Soluterials — Soluterials provides sustainable, innovative & high-performance pure aluminium.
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Germany, Belgium
Portfolio highlights
- Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
- DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the Länder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Funding Round, Series A, Series B
- Germany, India, Kenya
Portfolio highlights
- Uniper — Uniper is an international energy company with about 11,000 employees. They combine a balanced portfolio of technologically advanced large-scale assets with outstanding technical and commercial expertise. Uniper is a German energy company based in Dusseldorf, North Rhine-Westphalia. It was formed by the separation of E.ON's fossil fuel assetsinto a separate company that began operating on 1 January 2016.
- NamPower — NamPower is the national power utility of Namibia and specializes in the generation and transmission of electricity.
- Electrochaea — Electrochaea is commercializing a disruptive, scalable technology to convert electric power into methane, the principal component of natural gas. Using CO2 as a feedstock gas, power can be efficiently converted to renewable natural gas for power storage, for transportation fuels, or for transmission via a natural gas network. The company licensedtechnology from the University of Chicago and is led by the Nidus Partners, a St. Louis investment group specializing in renewable energy. Mich Hein, a Nidus Managing Partner, serves as CEO.Electrochaea has developed a commercially viable and disruptive solution for utility-scale energy storage, grid balancing, and carbon reuse. Their proprietary process converts low-cost and stranded electricity and carbon dioxide into pipeline-grade renewable gas for direct injection into the existing natural gas grid, a conversion process known as “power-to-gas”.
NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Seed, Series A, Series B
- Germany, United States
Portfolio highlights
- bNear — bNear is the digital space for all distributed- & hybrid teams - Safe and convenient in Microsoft Teams!
- Companyon Analytics — Companyon Analytics provides data security, cloud infrastructure, information technology, technical solutions, and consultancy services.
- Refined Laser Systems — Refined Laser Systems is a dynamic biophotonics company.It specialises in creating innovative laser systems for SRS-microscopy and quantum technology.
Zusammen gestalten wir die Unternehmen von morgen.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Funding Round, Series B
- Germany, Austria, Canada
Portfolio highlights
- AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.
- mbiomics — mbiomics is a biotechnology company.
- Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Series A, Funding Round
- Germany, United States, Finland
Portfolio highlights
- FERNRIDE — Fernride enables automated, sustainable logistics by combining the skills of remote drivers with autonomous technologies.
- FarmInsect — FarmInsect offers an automated solution for the local insect breeding at the farmer as animal feed for chickens, pork, and fish.
- Quantum Systems — Our vision is to become the global leader in providing aerial data for decision making by the use of our drones.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Funding Round
- Germany, United States, United Kingdom
Portfolio highlights
- Nosto — Use Powerful Personalization Made Easy on e-Commerce Platforms. Nosto generates a 10-30% Average Increase in Revenue.
- Minervax — MinervaX is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein : click to read more
- Seamless Therapeutics — Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Seamless technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes.
TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.
Show more
Investment focus
- Software, Information Technology, Manufacturing
- Seed, Funding Round, Series A
- Germany, United States
Portfolio highlights
- MiViA — From microstructure segmentation to grain size measurement! Our AI engine provides a fast and reliable metallographic analysis for metallic products.}
- BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
- volytica diagnostics — Our software enables customers to develop more economical battery systems, reduce operational risks and establish second-use concepts.
The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.
Show more
Investment focus
- Software, SaaS, Artificial Intelligence
- Seed, Funding Round, Grant
- Germany, United States
Portfolio highlights
- 3D Spark — Profitability and Sustainability Aligned using 3D Spark's Platform - Empowering Manufacturing with Insights and Efficiency!
- Stargazr — Stargazr is a AI-powered software that enables you to understand your financial data
- Neuralfinity — Neuralfinity provides computer AI services. They generalise machine learning models by utilising an ML API as a service.
Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.
Show more
Investment focus
- Software, SaaS, FinTech
- Series A, Seed, Series B
- Germany, Switzerland, United States
Portfolio highlights
- ContractHero — ContractHero is a leading digital contract management solution for business customers. The smart and easy-to-use software provides an overview of all current contracts, quickly identifies unnecessary costs and reduces risks from missed contract deadlines. As a result, companies have full control over their contracts and avoid missed deadlines andunnecessary costs.
- Lanes & Planes — Lanes & Planes GmbH is the Travel Management solution as Software-as-a-Service that truly maps all areas of the business travel in a digital way.
- Finanzguru — Finanzguru is an AI based financial assistant.
eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.
Show more
Investment focus
- Information Technology, Software, Manufacturing
- Series A, Funding Round, Series B
- Germany, United States, Italy
Portfolio highlights
- BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
- Build38 — Build38 is a global provider of mobile application protection solutions. Its solution represents a new generation of app-hardening technologies and service that protects apps from known and unknown attacks and opens the market to new digital business models. Build38 protects applications across various industries including automotive, financial,public transport and health care. Build38 is headquartered in Munich with global offices in Barcelona and Singapore. The company is a spin out of Giesecke + Devrient and ranks among the best IT Security startups in Germany. Build38 is an official GARTNER In-App Shielding Market Guide Vendor since 2019 and the first to combine: In-App Shielding + In-App Monitoring + AI-based In-App Reaction.
- QuoIntelligence — Our finished intelligence will significantly reduce your operational risks and allow you to make informed security decisions.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Switzerland, Germany, France
Portfolio highlights
- Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
bmp Ventures is an innovative Venture Capital Company from Berlin.
Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.
Show more
Investment focus
- Information Technology, Software, Manufacturing
- Seed, Funding Round, Series A
- Germany, United States, Austria
Portfolio highlights
- Neotiv — Enabling cognitive health
- RAYDIAX — We are Raydiax.Interventional only.Our goal is to reinvent computer tomography that is focussed on treatment.
- InLine-Med — Radiologists perform safe, precise & easy interventions with the InLine-Med surgical tools and assistance devices.
We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Funding Round, Series B
- Germany, Switzerland, United States
Portfolio highlights
- Ledgy — Digitize your cap table, automate equity plans and simplify compliance. Find out how leading companies use Ledgy to empower their employees and engage investors.
- HeyJobs — Intelligent recruiting | more hires with performance marketing | only qualified candidates | fast recruiting success | over 1,500 companies use HeyJobs to find employees
- Humanoo — HUMANOO | MAKING PEOPLE HEALTHIER! HUMANOO is the digital health platform for employees and insurance clients. We enable our users to improve their physical and mental health. Simple, effective, proven - all in one app. With customized programs and innovative eHealth solutions, we guide our users in the areas of fitness, physio, yoga, mindfulnessand nutrition to their self-imposed goals. For the first time, companies and insurance companies can use comprehensive decentralized analysis to understand the health of their employees or insurance clients and make it a measurable success. Our team currently consists of 65 employees from 15 nations with different talents. In our office in Berlin-Kreuzberg, software developers, designers, marketing and sales specialists work together with sports and nutrition scientists as well as yoga teachers and physiotherapists. What we share is the goal to motivate people to stay healthy.
Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, Germany, United Kingdom
Portfolio highlights
- Streaming21 — Checkout the full domain details of Streaming21.com. Click Buy Now to instantly start the transaction or Make an offer to the seller!
- Revolt Technology — News & Informations
- Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- Germany, Austria, Ireland
Portfolio highlights
- Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
- Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
bm|t supports innovative and growth-oriented companies in Thuringia with equity investments and venture capital.
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Funding Round, Series A
- Germany, United States
Portfolio highlights
- rooom.com — rooom is a global startup based in Germany, launched in 2019. The company’s experienceCloud is an all-in-one platform for creating, managing and promoting engaging 2D, 3D, AR & VR experiences. It works across all desktop and mobile devices. rooom’s experienceCloud is designed to cover the marketing and visualization needs of differentindustries through their comprehensive product portfolio. These include eventCloud (optimized for virtual events, exhibitions, conferences, meetings), spaceCloud (real estate, property, museums), productCloud (3D products, product showrooms) and immerseCloud (tours, guides, 3D books). rooom’s eventCloud is routinely hosting up to 200,000 users for hybrid events like IFA, Berlin and for global customers such as Porsche, Deutsche Telekom, DHL and E.ON. rooom has won over 20 awards, including the Global Eventex Award (twice), the Innovation & Excellence Award and the German Innovation Award.
- tediro — tediro develops a mobile robotics platform for multiple applications in healthcare primarily therapy and diagnostics
- Coachwhisperer — Coachwhisperer offers smart intercom and monitoring system for coaches and athletes.
Impacting the future of medicine.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, United Kingdom, The Netherlands
Portfolio highlights
- Aiolos Bio — Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by anaccomplished team with decades of drug development experience and leadership in the biotech industry.
- Tessellate BIO — Tessellate BIO is redefining synthetic lethality in cancer beyond homologous recombination deficiency, turning cancer patients into cancer surivivors.
- Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
Amino Collective is an investment firm. They enable entrepreneurs and scientists to establish businesses that generate a better future for all species on Earth. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, life science, and synthetic biology.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Pre-Seed
- Germany, United States, United Kingdom
Portfolio highlights
- Lindus Health — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
- Enveda Biosciences — Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California.
- Sensible Biotechnologies — Engineering cells to make better mRNA.
With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Series A, Funding Round
- Germany, United Kingdom
Portfolio highlights
- Doctorflix — Doctorflix is a medical education platform that allows doctors around the globe to learn about methods of treatment while accelerating their system-required professional development. We are on a mission to build an engine that simplifies and democratizes the consumption and exchange of medical knowledge by interlinking doctors, hospitals, andpharmaceutical companies.
- mama health — mama health is a platform to find others around the world living the same journey as you - and learn form each other's experience.
- DearEmployee — DearEmployee is the Workplace Mental Health Platform. As a corporate health start-up, we support employers in designing healthy and motivating working conditions for their employees in order to reduce mental stress and to increase employee productivity. Using the DearEmployee platform, companies can easily and digitally measure mental stress at theworkplace in a scientific way, and subsequently sign up to tailored health and HR measures. The solution also meets the legal requirements for mental health risk assessment in Germany.
S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.
Show more
Investment focus
- Biotechnology, Guides, Genetics
- Series B, Funding Round, Series A
- Germany
Portfolio highlights
- Innolume — Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power.
- Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
- Scienion — SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields – from early research to manufacturing.
Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.
Show more
Investment focus
- Software, Information Technology, Health Care
- Funding Round, Series A, Series B
- Germany, Italy, United States
Portfolio highlights
- memtime — memtime shows you everything you worked on during the day. Each program is recorded so that you can quickly remember. Add-on available for any software. | memtime
- SUSHI Bikes — SUSHI Bikes has developed the perfect e-bike for modern urban people.
- Kloster Kitchen — Kloster Kitchen is a monastery kitchen as the root of unique taste.
Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Funding Round, Seed, Series A
- Germany
Portfolio highlights
- miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
- Hemovent — Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
- aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, The Netherlands, Switzerland
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
- AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
UVC Partners is a Munich- and Berlin-based early-stage venture capital firm that invests in technology-based startups in the areas of enterprise software, industrial technologies, and mobility. The fund typically invests between € 0.5 - 10m initially and up to € 20m in total per company.
Show more
Investment focus
- Software, Information Technology, Artificial Intelligence
- Seed, Series A, Series B
- Germany, Switzerland, Denmark
Portfolio highlights
- Stabl Energy — Stabl Energy is a developer of a technology that significantly improves battery storage systems.
- Proxima Fusion — We are a European fusion energy startup pursuing the clearest path to grid deployment.
- ChargeX — ChargeX provides electric car charging solutions. Tobias Wagner, Michael Masnitza, and Johannes Engeln founded it in 2017, with its headquarters in Munich in Germany.
German Federal Ministry of Education and Research (BMBF)
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Grant, Seed, Series B
- Germany, United States, Denmark
Portfolio highlights
- InflaRx — InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.In April 2018, InflaRx conducted a USD 117 million totalgross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany.
- Evotec — Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances,development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure.Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases.
- NVision Imaging Technologies — NVision Imaging Technologies is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation.
The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Private Equity, Funding Round
- France, United States, Germany
Portfolio highlights
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
- Ariceum Therapeutics — Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Seed, Series A, Series B
- Germany, United States, Switzerland
Portfolio highlights
- Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
- anvajo — Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof.
- Navignostics — Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.
96
Normal
0
false
false
false
EN-GB
X-NONE
X-NONE
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Series A, Seed, Series B
- Germany, Finland, The Netherlands
Portfolio highlights
- Surgify — Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa).
- ATRO Medical — ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype.
- microDimensions — microDimensions provides digital pathology software and services: image analysis, 3D histology reconstruction, protein multiplexing, stereology, image registration.
Collaboration with outstanding initiators with exceptional insights, from inception through all levels of progress. Lima Ventures supports visionary founders as well as provides certain services to early startups. We seek innovative technology-driven entrepreneurs who generate and lead companies that will inspire millions.
Show more
Investment focus
- Artificial Intelligence, Software, FinTech
- Seed, Pre-Seed, Funding Round
- Turkey, Estonia, Germany
Portfolio highlights
- VRLab Academy — VRLab Academy specializes in implementing advanced virtual science education to institutions. It focuses on waste-free, attractive, and useful design to makes advanced virtual science education possible. The company aims to evolve the educational environment where students will improve their scientific skills and learn all about it from firsthand.
- Studio Billion — Studio Billion is a game development company that develops applications, games, and projects for different platforms. Studio Billion is headquartered in Istanbul, Turkey.
- Enqura Information Technologies — Enqura Information Technologies offers advanced technologies in conjunction with human resources as reasonable solutions. Enqura develops creative solutions in the field of digital transformation. They provide innovative and end-to-end solutions to several industries, primarily finance and insurance.
Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale.
In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.
Show more
Investment focus
- Internet, E-Commerce, Biotechnology
- Series A, Seed, Series B
- Germany, United States, Switzerland
Portfolio highlights
- VYTAL — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
- ZAGENO — ZAGENO is a multi-vendor, online marketplace of life science products which, by simplifying the procurement process, saves more time for science.
- Hypatos — Manual document processing is a major cost driver. Hypatos' deep learning tech automates complex document processing tasks. Make back office more efficient!
IBB Ventures is a venture capital and mezzanine arm of Investitionsbank Berlin specializing in seed/startup, early venture, and mid venture investments. The firm invests in technology-oriented companies and companies from the creative industries. It typically invests in information and communication sector with a focus on hardware andsoftware, network technology, new media, and internet and mobile technologies; life science sector with a focus on biotechnology and media technology; and industrial technologies sector with a focus on software, PPS, supply chain management, micro and nanotechnology, environmental and power technology, automation, manufacturing technology, transport technology and logistics, and new materials. The firm also invests in movies, broadcast, television, publisher, music, entertainment, advertising, fashion, design, architecture, multimedia, games, software, and art and culture. It invests in companies based in Berlin. It typically invests between €0.25 million ($0.32 million) and €3 million ($3.83 million) per transaction. The firm prefers to take a board seat in its portfolio companies. IBB Ventures was founded in 1997 and is based in Berlin, Germany.
Show more
Investment focus
- Software, Health Care, Internet
- Seed, Funding Round, Series A
- Germany, United States, United Kingdom
Portfolio highlights
- nuwo — Workplace as-a-Service. nuwo is the #1 platform for financing, equipping and managing hybrid workspaces
- MERSOR — MERSOR is an online marketplace for stylish and pre-curated gifts with a unique and innovative customer experience. We aim to make gifting easy, fast and fun again by not only providing the perfect gift but also assisting the customers in their overall gift management.
- Wonnda — Wonnda is the digital infrastructure where buyers and suppliers collaboratively build the consumer products of tomorrow
Occident macht Investments in Deep Tech Startups aus den Bereichen Lifesciences, Hightech und Digital. Finanzierung ab Seed-Finanzierungsrunde
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Series A, Series C, Funding Round
- Germany, Switzerland
Portfolio highlights
- ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
- iThera Medical — Due to its spatiotemporal resolution, penetration depth, sensitivity and specificity, optoacoustic imaging (OAI) can be used for a multitude of applications.
- Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research
BlueYard backs founders building the interconnected elements that can become the fabric of our future.
Show more
Investment focus
- Software, Cryptocurrency, Internet
- Seed, Series A, Funding Round
- United States, Germany, France
Portfolio highlights
- Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
- AnySignal — AnySignal was developed to reimagine how RF capabilities are delivered for the most difficult tasks around the globe. offers complete solutions for modern aircraft, satellites, and national security that span communications, radar, navigation, and RF sensing. Current solutions are overpriced, unimaginative, and provide little end-to-end capability.To shift this paradigm, they are bringing the appropriate talent, procedures, and technologies together. They are developing communications systems for satellites, launchers, space stations, and aircraft. They provide full-stack connectivity solutions that include software modems, hardware for use in flight and on the ground, data management software, ground station integration software, and vehicle telemetry software.
- Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.
Show more
Investment focus
- Food and Beverage, Food Processing, Biotechnology
- Series A, Seed, Series B
- United States, Israel, United Kingdom
Portfolio highlights
- ENOUGH — ENOUGH makes protein sustainable by producing ABUNDA mycoprotein, made by fermenting fungi with the natural sugars from grains. It is a whole protein with all 9 essential amino acids & rich in fibre. It is a B2B ingredient, neutral in taste and fibrous in texture, like meat. The most sustainable
- PoLoPo — PoLoPo is a biotech company that produces proteins on a large scale and according to specifications. PoLoPo develops a "superAA" plant by employing directed metabolic engineering techniques and fully utilizing plants' capacity as various metabolite and green protein factories. A significant amount of free amino acids can be producedby the superAA. The increased production of amino acids is then translated into an increase in the scale at which proteins are produced in plant organs.
- Wanda Fish Technologies — Wanda Fish is an innovative FoodTech company with a platform that produces a wide variety of delicious fish fillets using sustainable cell-cultivation practices.
TVM Capital Group is an affiliation of globally acting venture capital and private equity firms with an operating track record of more than 30 years.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Funding Round, Series C
- United States, Germany, United Kingdom
Portfolio highlights
- Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
- Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
- Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series C, Series B, Series A
- United States, The Netherlands, Germany
Portfolio highlights
- FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- GT Medical Technologies — At GT Medical Technologies, our purpose is Improving the Lives of Patients with Brain Tumors. GammaTile Therapy is Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors.
start-ups, SMEs, technology, co-investment
Show more
Investment focus
- Seed
- Germany
Portfolio highlights
- Filuta AI — Operationalized Composite Artificial Intelligence
- Resistell AG — Resistell is a antibiotic resistance test.
- iThera Medical — Due to its spatiotemporal resolution, penetration depth, sensitivity and specificity, optoacoustic imaging (OAI) can be used for a multitude of applications.
LSP BioVentures is a venture capital fund focused on opportunities in the life science arena. Based in Cambridge (MA) in the USA; the fund’s management combines the strength of its parent company, Life Sciences Partners Venture Capital firm in Europe and a dedicated team of experts in the USA.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Germany, United Kingdom
Portfolio highlights
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
- HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.
EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totalling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totalling €660 million. EQT Ventures III launched in 2022, with commitments totalling €1.1 billion, making it the biggest European Venture Capital fund committed to early stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris and San Francisco, taking a locals with locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has data-driven approach and has driven more than $100 million in portfolio company investments.
Show more
Investment focus
- Software, Information Technology, SaaS
- Series A, Series B, Seed
- Sweden, Germany, United States
Portfolio highlights
- Fly.io — Fly.io offers an Application Delivery Network (ADN) intended to help website owners get connected with their customers easily. The company's application delivery network uses a global network of servers to accept visitor traffic, run middleware on requests, then route them to backend applications, enabling website owners to direct theirvisitors to their respective sites securely and in a few clicks.
- Verkor — Verkor is a battery cell manufacturer whose goal is to increase the production of low-carbon batteries to fulfill the growing demand for electric vehicles. The company focuses on the development of low-carbon batteries with a carbon footprint that is many times smaller than standard batteries. This reduces the logistics footprint, includingemissions, and provides businesses with batteries that are very inexpensive and use carbon-free electricity.
- Volt.io — Increase retention and digital sales by allowing your customers to initiate direct payments, from their bank accounts to yours in real-time. Your checkout in super-drive, powered by Volt.
Delivery Hero Ventures is backed by Delivery Hero, a truly global food delivery platform - whose network, distribution and expertise can be harnessed to help our portfolio companies fulfill their global ambitions.
Show more
Investment focus
- E-Commerce, Information Technology, Food Delivery
- Series A, Seed, Series B
- Singapore, Egypt, Brazil
Portfolio highlights
- Qashier — One Qashier solution streamlines POS & payment operations empowering businesses to thrive in the digital economy. Be More with Qashier.
- Flash Coffee — Flash Coffee is a tech-enabled coffee chain that customers use their app to order and pay online, choosing to pick up orders from one of the Flash Coffee’s storefronts or order for delivery through major platforms in each market. Flash Coffee was founded in 2019 and is headquartered in Singapore.
- Bluu Seafood — Cultivated Seafood Made From Fish Cells. Tastier, Healther and More Sustainable.
Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series A, Series B, Funding Round
- France, United States, Germany
Portfolio highlights
- Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
- Allozymes — Allozymes applies its proprietary platform technology to rapidly develop novel enzymes, revolutionizing the way that industries manufacture complex natural
- Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.
Show more
Investment focus
- Medical, Therapeutics, Biotechnology
- Series A, Series B, Funding Round
- Germany
Portfolio highlights
- Siltectra — SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.
- Isarna Therapeutics — Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
PVP is a private venture capital firm based in Berlin, investing in early-stage healthcare companies across Europe with a focus on medical device, digital health, and platform technology companies.
Peppermint VenturePartners was established in 2008 by Ingeborg Neumann, Dr. Joachim Rautter and Dr. Klaus Stöckemann.
Show more
Investment focus
- Health Care, Medical, Biotechnology
- Series A, Series B, Series C
- Germany, Belgium
Portfolio highlights
- Miracor Medical — Miracor Medical is a medical device company developing disruptive solutions to treat severe heart diseases
- CryoTherapeutics — USING CRYOTHERAPY TO TREAT AND PREVENT HEART ATTACKS
- CEVEC Pharmaceuticals — Platforms for AAV manufacturing, for Adenoviral vectors, Lentiviral vectors, Oncolytic viruses, Exosomes and for complex recombinant proteins.
home meta desc
Show more
Investment focus
- Software, Manufacturing, Health Care
- Funding Round, Private Equity, Series B
- United States, United Kingdom, Germany
Portfolio highlights
- XSuite Group — xSuite is a software company that creates applications for document-based processes such as accounting, purchasing, and file management.
- Konges Sløjd — Konges Sløjd is a creative brand that salutes the wild, varied, and perfectly imperfect life with children. Our aim is to make thoughtful and quality-conscious designs using our unique signature prints and color palette, whilst dropping in an imaginative humorous aesthetics. All clothing is soft to the touch keeping your little ones comfy and safecome rain, shine, good days, or rough nights.
- Vakantie Discounter — Holiday Discounter (part of Elmar Reizen BV) was started in 2000 in Arnhem and has developed thanks to fully concentrate on cheap holidays. A team of staff called in the early every day the tour operators or airlines to get the best deals. And actually we still do, only now much more automated and we now operate from Amsterdam.
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- Belgium, Germany, The Netherlands
Portfolio highlights
- CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
- Scenic Biotech — We are pioneers in the discovery of genetic modifiers to enable the development of transformative therapeutics.
- Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Series B, Series A
- Denmark, Sweden, Switzerland
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Pacira Pharmaceuticals Inc. operates as a pharmaceutical company which engages in the development and manufacturing of injectable pharmaceutical products. Pacira Pharmaceuticals Inc. was formerly known as DepoTech Corp. was formerly as SkyePharma Inc. and changed its name to Pacira Pharmaceuticals Inc. in June, 2007. The company was founded in 1989and is based in San Diego, California. Pacira Pharmaceuticals Inc. operates as a subsidiary of Pacira, Inc.
Show more
Investment focus
- Biotechnology, Medical, Pharmaceutical
- Funding Round, Convertible Note, Seed
- United States, Germany
Portfolio highlights
- CarthroniX — CarthroniX is a pharmaceutical company that offers small molecule based therapy, wound healing, skin regeneration, and novel solutions.
- Spine BioPharma — specializes in non-surgical therapies that will reduce pain, restore function, and slow or stop pathological spinal disease progression without the use of opioids.
- CODA Biotherapeutics — Coda Biotherapeutics makes tunable gene therapy to treat severe neurological disorders.
TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Funding Round, Series A, Series B
- Canada, United States, Germany
Portfolio highlights
- Egg Medical — Egg Medical is a medical device company that offers EGGNEST, a passive protection designed to drastically reduce scatter radiation exposure for the entire cath lab team without disruption to workflow. It is an in integrated work platform built on a carbon fiber sled base designed to drastically reduce scatter radiation exposure without disruptingworkflow.
- Centogene — CENTOGENE is one of the largest genetic biotech companies worldwide, the European market leader, and one of the global leaders in genetic diagnostic analyses of rare inherited diseases. Transforming global genetic data into medical decisions, that are focused on creating broarder awareness for patients of all ethnicities around the world. CENTOGENEis a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for Patients. With headquarters in Rostock, Germany and further operations in Berlin, Germany as well as Cambridge, Massachusetts, USA, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients with rare diseases and their families. CENTOGENE provides the full spectrum of modern methods and technology for human genetics analysis; it is active in research and is constantly developing new and innovative products for human genetics.
- Recurv Pharma — Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers,has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours.
HBM Partners focuses on venture, growth and buy-out financings of private companies as well as investments in public companies.The HBM funds invest in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. Their team supports the growth of the portfolio companies through allstages of development, focusing on adding value by leveraging its experience and HBM's world-wide network in the industry. Investments usually range between $5 million to $50 million.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series B, Funding Round, Series C
- United States, Germany, Switzerland
Portfolio highlights
- Dren Bio — Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
- Neuron23 — Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
- Mineralys Therapeutics — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
Investors by industry
Artificial intelligence
Energy
Community
Proptech
Consumer
Media (entertainment)
Marketplace
Impact
Hardware
Gaming
EdTech
FinTech
Biotech
Climate
Transportation
Health Care
Enterprise
Agriculture (agtech)
Sustainability
Venture Capital
Restaurants
Web3
Photography
Infrastructure
Beauty
Fashion
Mobile Apps
B2B
Publishing
Clean Energy
LGBT
Sporting Goods
Renewable Energy
Oil and Gas
Education
Big Data
Cryptocurrency
Video Games
Payments
Organic Food
Food and Beverage
Finance
Financial Services
Retail
Real Estate
Medical
Art
Social Network
Wellness
Music
Internet
Celebrity
Google
Facebook
Franchise
Android
Blockchain
Social Impact
Legal
Mobile
Enterprise Software
Local
Construction
eSports
Sports
Email
Manufacturing
Social Media
Digital Media
Fitness
Mobile Advertising
Hospitality
Travel
Recruiting
Biotechnology
Cannabis
Platforms
Wine And Spirits
Medical Device
Automotive
Crowdfunding
Social
CleanTech
InsurTech
SaaS
Software
Film
Life Science
Theatre
Non Profit
Investors by country
Ireland
United Kingdom
India
South Korea
Australia
Canada
Germany
New Zealand
United States
Asia
LATAM
Middle East
Africa
Saudi Arabia
Europe
Indonesia
Singapore
Oceania
Japan
South Africa
Qatar
Vietnam
Austria
Sri Lanka
Brazil
Spain
Argentina
Armenia
China
Belize
Bulgaria
Belarus
Belgium
Costa Rica
Bahrain
Bermuda
Switzerland
Chile
Cameroon
Czech Republic
Algeria
Colombia
Denmark
Egypt
Ethiopia
Faroe Islands
Ecuador
Estonia
Ghana
Finland
Hungary
France
Gibraltar
Croatia
Georgia
Hong Kong
Greece
Barbados
Bangladesh
Italy
Jordan
Lithuania
Jersey
Kuwait
Cayman Islands
Kazakhstan
Lebanon
Liberia
Kenya
Liechtenstein
Mali
Myanmar
Mauritius
Panama
Malaysia
Malta
Mexico
Nicaragua
Norway
Peru
Philippines
Israel
Cambodia
Morocco
Pakistan
Puerto Rico
Portugal
Romania
Sweden
Rwanda
Taiwan
Serbia
Seychelles
Tunisia
Slovenia
Senegal
Turkey
El Salvador
San Marino
Sierra Leone
Togo
Thailand
Tajikistan
Zimbabwe
Uruguay
Venezuela
Tanzania
Uganda
Uzbekistan
Zambia
Ukraine
Poland
Russian Federation
Nigeria
Azerbaijan
Guatemala
Iraq
Namibia
Iceland
Bahamas
United Arab Emirates
Honduras
Bolivia
Isle of Man
Luxembourg
Cyprus
Latvia
Oman
VC Funds in Germany by industry
Transportation
FinTech
Enterprise
Consumer
Biotech
Health Care
Climate
Sustainability
Impact
Proptech
SaaS
Marketplace
Community
Artificial intelligence
Agriculture (agtech)
Hardware
EdTech
Gaming
Media (entertainment)
Energy
Crowdfunding
Venture Capital
Restaurants
Real Estate
Fashion
Financial Services
Mobile Apps
Cryptocurrency
Education
Finance
Payments
Food and Beverage
Wine And Spirits
Video Games
Organic Food
Medical
Email
Medical Device
Wellness
Internet
Social Media
Social Network
Music
Manufacturing
Art
Digital Media
Blockchain
Mobile
Android
Social Impact
Construction
Local
Legal
Software
Sports
Enterprise Software
eSports
Fitness
Travel
Hospitality
CleanTech
InsurTech
Automotive
Recruiting
Mobile Advertising
Platforms
Cannabis
Biotechnology
Retail
Infrastructure
Social
Beauty
Web3
B2B
Life Science
Sporting Goods
Big Data
Photography
Publishing
Renewable Energy
Clean Energy